tiprankstipranks
Advertisement
Advertisement

BCRX Stock Latest News

Is BCRX a Buy, Before Earnings?
Pre-EarningsIs BCRX a Buy, Before Earnings?
17h ago
BCRX
BioCryst appoints David Jenkins as chief scientific officer
PremiumThe Fly
BioCryst appoints David Jenkins as chief scientific officer
20d ago
BCRX
BioCryst resumed with a Neutral at JPMorgan
PremiumThe Fly
BioCryst resumed with a Neutral at JPMorgan
22d ago
BCRX
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
PremiumThe Fly
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
28d ago
ASND
BCRX
BioCryst price target raised to $14 from $13 at RBC Capital
PremiumThe Fly
BioCryst price target raised to $14 from $13 at RBC Capital
28d ago
BCRX
BioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating
PremiumRatingsBioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating
1M ago
BCRX
BioCryst price target raised to $29 from $27 at Cantor Fitzgerald
Premium
The Fly
BioCryst price target raised to $29 from $27 at Cantor Fitzgerald
1M ago
BCRX
Analyst Reaffirms Buy on BioCryst as Company Streamlines R&D, Maintains 2026 Outlook and Sets $16 Price Target
Premium
Ratings
Analyst Reaffirms Buy on BioCryst as Company Streamlines R&D, Maintains 2026 Outlook and Sets $16 Price Target
1M ago
BCRX
BioCryst Advances Rare Disease Pipeline Amid Cost Controls
PremiumCompany Announcements
BioCryst Advances Rare Disease Pipeline Amid Cost Controls
1M ago
8K
BCRX
BioCryst to discontinue internal discovery programs, close Alabama facility
PremiumThe Fly
BioCryst to discontinue internal discovery programs, close Alabama facility
1M ago
BCRX
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
1M ago
CGC
IRE
BioCryst Shareholders Approve Expanded Equity Incentive Plan
PremiumCompany Announcements
BioCryst Shareholders Approve Expanded Equity Incentive Plan
2M ago
8K
BCRX
BioCryst to present new Orladeyo data at EAACI
PremiumThe FlyBioCryst to present new Orladeyo data at EAACI
2M ago
BCRX
BioCryst Earnings Call: ORLADEYO Momentum vs. Risks
Premium
Company Announcements
BioCryst Earnings Call: ORLADEYO Momentum vs. Risks
3M ago
BCRX
BioCryst price target raised to $28 from $25 at Citizens
Premium
The Fly
BioCryst price target raised to $28 from $25 at Citizens
3M ago
BCRX
BioCryst reports Q1 EPS ($2.98), consensus 11c
PremiumThe Fly
BioCryst reports Q1 EPS ($2.98), consensus 11c
3M ago
BCRX
BioCryst backs FY26 revenue view $635M-$660M, consensus $650.22M
PremiumThe Fly
BioCryst backs FY26 revenue view $635M-$660M, consensus $650.22M
3M ago
BCRX
BioCryst Earnings Call: Growth, Pipeline And New Risks
PremiumCompany Announcements
BioCryst Earnings Call: Growth, Pipeline And New Risks
3M ago
BCRX
BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target
PremiumRatings
BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target
3M ago
BCRX
BioCryst Posts Q1 2026 Results, Maintains Growth Outlook
PremiumCompany AnnouncementsBioCryst Posts Q1 2026 Results, Maintains Growth Outlook
3M ago
8K
BCRX
BioCryst Licenses European Rights to HAE Drug Navenibart
Premium
Company Announcements
BioCryst Licenses European Rights to HAE Drug Navenibart
3M ago
8K
BCRX
BioCryst enters navenibart license agreement with Neopharmed Gentili
Premium
The Fly
BioCryst enters navenibart license agreement with Neopharmed Gentili
3M ago
BCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >